ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.340
-0.020 (-0.85%)
At close: Nov 28, 2025, 1:00 PM EST
2.380
+0.040 (1.71%)
After-hours: Nov 28, 2025, 4:08 PM EST
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 2.92M EUR in the quarter ending September 30, 2025, a decrease of -26.78%. This brings the company's revenue in the last twelve months to 16.07M, down -12.57% year-over-year. In the year 2024, ProQR Therapeutics had annual revenue of 19.55M with 196.41% growth.
Revenue (ttm)
16.07M EUR
Revenue Growth
-12.57%
P/S Ratio
12.89
Revenue / Employee
96,773 EUR
Employees
166
Market Cap
246.51M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.55M | 12.95M | 196.41% |
| Dec 31, 2023 | 6.59M | 2.24M | 51.27% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | 1.35M | 131.10% |
| Dec 31, 2020 | 1.03M | -904.00K | -46.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRQR News
- 23 days ago - ProQR Announces Third Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 25 days ago - ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript - Seeking Alpha
- 5 weeks ago - ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 - GlobeNewsWire
- 6 weeks ago - ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewsWire
- 4 months ago - ProQR Announces Second Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 4 months ago - ProQR Announces Upcoming Presentation at RNA Editing Summit - GlobeNewsWire
- 5 months ago - ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewsWire
- 7 months ago - ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewsWire